Lab Essentials
AMPIVIEW® RNA probes
Enabling Your Projects 
GMP Services
Bulk Solutions
Research Travel Grant
Have You Published Using an Enzo Product?
Enzo Welcomes Chris Gildea, CFO
Enzo is pleased to announce the appointment of Chris Gildea as the company’s new Chief Financial Officer.
Chris joins Enzo with extensive experience in corporate finance, strategic planning, and organizational leadership within high-growth, science-driven industries. Over the course of his career, he has built a strong track record in financial stewardship, business transformation, and guiding global operations—expertise that directly supports Enzo’s continued growth and long-term strategic objectives.
Most recently, Chris served as Chief Financial Officer at Biocare Medical, serving customers with both reagents and instrumentation for diagnostics and life science discovery. Over the course of his career, he has also held key leadership roles in sales and commercial operations with BD Biosciences, Wheaton Industries, and Biocare Medical, in addition to leading R&D at Biocare Medical and Global Marketing for BD Diabetes Care. This broad perspective gives him a deep understanding of how innovation, customer insight, and disciplined financial leadership come together to drive growth in life sciences companies.
At Enzo Life Sciences, Chris will play a key role in helping accelerate the company’s growth strategy and strengthening its leadership in proteomics, genomics, and small molecule science, empowering researchers and advancing scientific discovery worldwide.
“Chris’s leadership style, strategic thinking, and depth of financial expertise make him an outstanding addition to our executive team,” said Jason Apter, CEO of Enzo. “We are excited to welcome him and look forward to the contributions he will bring to our mission.” Chris’s appointment represents both continuity and forward momentum as Enzo enters its next phase of strategic growth and operational advancement.
We look forward to this next chapter with confidence, enthusiasm, and forward momentum—positioning Enzo for long-term success.
Chris joins Enzo with extensive experience in corporate finance, strategic planning, and organizational leadership within high-growth, science-driven industries. Over the course of his career, he has built a strong track record in financial stewardship, business transformation, and guiding global operations—expertise that directly supports Enzo’s continued growth and long-term strategic objectives.
Most recently, Chris served as Chief Financial Officer at Biocare Medical, serving customers with both reagents and instrumentation for diagnostics and life science discovery. Over the course of his career, he has also held key leadership roles in sales and commercial operations with BD Biosciences, Wheaton Industries, and Biocare Medical, in addition to leading R&D at Biocare Medical and Global Marketing for BD Diabetes Care. This broad perspective gives him a deep understanding of how innovation, customer insight, and disciplined financial leadership come together to drive growth in life sciences companies.
At Enzo Life Sciences, Chris will play a key role in helping accelerate the company’s growth strategy and strengthening its leadership in proteomics, genomics, and small molecule science, empowering researchers and advancing scientific discovery worldwide.
“Chris’s leadership style, strategic thinking, and depth of financial expertise make him an outstanding addition to our executive team,” said Jason Apter, CEO of Enzo. “We are excited to welcome him and look forward to the contributions he will bring to our mission.” Chris’s appointment represents both continuity and forward momentum as Enzo enters its next phase of strategic growth and operational advancement.
We look forward to this next chapter with confidence, enthusiasm, and forward momentum—positioning Enzo for long-term success.